{"id":"ftc-tdf-fdc","safety":{"commonSideEffects":[{"rate":null,"effect":"Nausea"},{"rate":null,"effect":"Diarrhea"},{"rate":null,"effect":"Headache"},{"rate":null,"effect":"Renal impairment"},{"rate":null,"effect":"Bone density loss"},{"rate":null,"effect":"Lactic acidosis"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Emtricitabine (FTC) and tenofovir disoproxil fumarate (TDF) are both nucleoside/nucleotide reverse transcriptase inhibitors that work by incorporating into the growing HIV DNA chain and causing chain termination. Together in this fixed-dose combination, they provide complementary antiretroviral activity against HIV-1 and HIV-2, reducing viral load and slowing disease progression.","oneSentence":"FTC/TDF is a fixed-dose combination of two nucleoside reverse transcriptase inhibitors that block HIV reverse transcriptase to prevent viral replication.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T01:13:34.140Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"HIV-1 infection (treatment)"},{"name":"HIV-1 pre-exposure prophylaxis (PrEP)"}]},"trialDetails":[{"nctId":"NCT04223791","phase":"PHASE3","title":"Switch to Doravirine/Islatravir (DOR/ISL) in Human Immunodeficiency Virus 1 (HIV-1) Participants Treated With Bictegravir/Emtricitabine/Tenofovir Alafenamide (BIC/FTC/TAF) (MK-8591A-018)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2020-02-18","conditions":"HIV Infection","enrollment":643},{"nctId":"NCT02881320","phase":"PHASE2, PHASE3","title":"Study of Bictegravir/Emtricitabine/Tenofovir Alafenamide Fixed Dose Combination in Adolescents and Children With Human Immunodeficiency Virus-1","status":"ACTIVE_NOT_RECRUITING","sponsor":"Gilead Sciences","startDate":"2016-09-21","conditions":"HIV-1 Infection","enrollment":177},{"nctId":"NCT06337032","phase":"PHASE4","title":"A Study to Provide Continued Access to Study Drug to Children and Adolescents Who Have Completed Clinical Studies Involving Gilead HIV Treatments","status":"RECRUITING","sponsor":"Gilead Sciences","startDate":"2024-08-27","conditions":"HIV-1-infection","enrollment":350},{"nctId":"NCT07202546","phase":"PHASE2","title":"A Phase 2b Study Evaluating Oral VH4524184 Regimens in Treatment Naïve Persons With HIV-1 (INNOVATE Study)","status":"RECRUITING","sponsor":"ViiV Healthcare","startDate":"2026-02-11","conditions":"HIV Infections","enrollment":150},{"nctId":"NCT06101342","phase":"PHASE2","title":"Study of Lenacapavir and Emtricitabine/Tenofovir Disoproxil Fumarate (F/TDF) for Prevention of HIV in People Who Inject Drugs (HPTN 103)","status":"ACTIVE_NOT_RECRUITING","sponsor":"Gilead Sciences","startDate":"2023-12-13","conditions":"Pre-Exposure Prophylaxis of HIV Infection","enrollment":181},{"nctId":"NCT05052996","phase":"PHASE2","title":"Study Evaluating the Safety and Efficacy of Islatravir in Combination With Lenacapavir in Virologically Suppressed People With HIV","status":"ACTIVE_NOT_RECRUITING","sponsor":"Gilead Sciences","startDate":"2021-10-05","conditions":"HIV-1 Infection","enrollment":142},{"nctId":"NCT04233879","phase":"PHASE3","title":"Study of Doravirine/Islatravir (DOR/ISL 100 mg/0.75 mg) to Evaluate the Antiretroviral Activity, Safety, and Tolerability in Treatment-Naïve Participants With Human Immunodeficiency Virus Type 1 (HIV-1) Infection (MK-8591A-020)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2020-02-28","conditions":"HIV-1 Infection","enrollment":599},{"nctId":"NCT01854775","phase":"PHASE2, PHASE3","title":"Study to Evaluate the Pharmacokinetics, Safety, and Antiviral Activity of the Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Alafenamide (E/C/F/TAF) Single Tablet Regimen (STR) in HIV-1 Infected Antiretroviral Treatment-Naive Adolescents and Virologically Suppressed Children","status":"COMPLETED","sponsor":"Gilead Sciences","startDate":"2013-05-06","conditions":"Acquired Immune Deficiency Syndrome (AIDS), HIV Infections","enrollment":129},{"nctId":"NCT06544733","phase":"PHASE2, PHASE3","title":"Study of Oral Weekly GS-1720 and GS-4182 Versus Biktarvy in People With HIV-1 Who Are Virologically Suppressed","status":"ACTIVE_NOT_RECRUITING","sponsor":"Gilead Sciences","startDate":"2024-08-20","conditions":"HIV-1-Infection","enrollment":675},{"nctId":"NCT05979311","phase":"PHASE3","title":"A Study to Evaluate the Efficacy, Safety, and Tolerability of Using an Oral Once-daily 2 Drug Regimen Compared to an Oral Once-daily 3 Drug Regimen for the Treatment of Human Immunodeficiency Virus (HIV)-1 in Adults Who Have Not Previously Taken Antiretroviral Therapy","status":"ACTIVE_NOT_RECRUITING","sponsor":"ViiV Healthcare","startDate":"2024-02-09","conditions":"HIV, HIV Infections","enrollment":473},{"nctId":"NCT05911360","phase":"PHASE3","title":"A Study to Evaluate Efficacy, Safety and Tolerability in Antiretroviral Therapy (ART)-Experienced Participants of at Least 50 Years of Age Living With Human Immunodeficiency Virus (HIV) With Virologic Suppression Who Switch to DTG/3TC FDC From BIC/FTC/TAF","status":"ACTIVE_NOT_RECRUITING","sponsor":"ViiV Healthcare","startDate":"2023-01-31","conditions":"HIV, HIV Infections","enrollment":205},{"nctId":"NCT06613685","phase":"PHASE2, PHASE3","title":"Study of Oral Weekly GS-1720 and GS-4182 Compared With Biktarvy in People With HIV-1 Who Have Not Been Treated","status":"ACTIVE_NOT_RECRUITING","sponsor":"Gilead Sciences","startDate":"2024-10-21","conditions":"HIV-1-infection","enrollment":675},{"nctId":"NCT06333808","phase":"PHASE3","title":"Study to Compare Bictegravir/Lenacapavir Versus Current Therapy in People With HIV-1 Who Are Successfully Treated With Biktarvy","status":"ACTIVE_NOT_RECRUITING","sponsor":"Gilead Sciences","startDate":"2024-03-25","conditions":"HIV-1-infection","enrollment":577},{"nctId":"NCT05502341","phase":"PHASE2, PHASE3","title":"Study to Compare Bictegravir/Lenacapavir Versus Current Therapy in People With HIV-1 Who Are Successfully Treated With a Complicated Regimen","status":"ACTIVE_NOT_RECRUITING","sponsor":"Gilead Sciences","startDate":"2022-08-16","conditions":"HIV-1-infection","enrollment":689},{"nctId":"NCT06101329","phase":"PHASE2","title":"Study of Lenacapavir and Emtricitabine/Tenofovir Disoproxil Fumarate (F/TDF) in Prevention of HIV in Cisgender Women in the United States (HPTN 102)","status":"ACTIVE_NOT_RECRUITING","sponsor":"Gilead Sciences","startDate":"2023-11-17","conditions":"Pre-Exposure Prophylaxis of HIV Infection","enrollment":253},{"nctId":"NCT06513312","phase":"PHASE2","title":"Study of Lenacapavir Taken Twice a Year for HIV Pre-Exposure Prophylaxis (PrEP)","status":"ACTIVE_NOT_RECRUITING","sponsor":"Gilead Sciences","startDate":"2024-10-07","conditions":"Pre-Exposure Prophylaxis of HIV Infection","enrollment":268},{"nctId":"NCT04880395","phase":"PHASE4","title":"Dolutegravir-Lamivudine for naïve HIV-Infected Patients With ≤200 CD4/mm3","status":"COMPLETED","sponsor":"Fundación Huésped","startDate":"2021-05-17","conditions":"HIV-1-infection","enrollment":265},{"nctId":"NCT06787976","phase":"PHASE4","title":"Effect of Dolutegravir Compared With Darunavir/Cobicistat on the Severity of Neuropsychiatric Effects al 12 Weeks in Antirretroviral Treatment-Naive Adults.","status":"NOT_YET_RECRUITING","sponsor":"Instituto Mexicano del Seguro Social","startDate":"2025-06-19","conditions":"HIV, Insomnia, Anxiety","enrollment":140},{"nctId":"NCT04442737","phase":"PHASE4","title":"A Study of Darunavir/Cobicistat/Emtricitabine/Tenofovir Alafenamide (D/C/F/TAF) Evaluated as a Fixed Dose Combination Regimen in Participants Switching From an Integrase Inhibitor Who Have Experienced Rapid Weight Gain","status":"COMPLETED","sponsor":"Janssen Scientific Affairs, LLC","startDate":"2020-07-01","conditions":"HIV-1","enrollment":103},{"nctId":"NCT03547908","phase":"PHASE3","title":"Safety and Efficacy of Bictegravir/Emtricitabine/Tenofovir Alafenamide Versus Dolutegravir + Emtricitabine/Tenofovir Disoproxil Fumarate in Treatment Naive, HIV-1 and Hepatitis B Co-Infected Adults","status":"COMPLETED","sponsor":"Gilead Sciences","startDate":"2018-05-30","conditions":"HIV-1/HBV Co-Infection","enrollment":244},{"nctId":"NCT02652260","phase":"PHASE2","title":"Effects of Switching From ATRIPLA™ (Efavirenz, Tenofovir, Emtricitabine) to MK-1439A (Doravirine, Tenofovir, Lamivudine) in Virologically-Suppressed Participants (MK-1439A-028)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2016-03-04","conditions":"HIV-1, Central Nervous System","enrollment":86},{"nctId":"NCT03227861","phase":"PHASE3","title":"A Study to Evaluate the Efficacy and Safety of (D/C/F/TAF) Once Daily Fixed Dose Combination (FDC) Regimen in Newly Diagnosed, Antiretroviral Treatment-naive Human Immunodeficiency Virus Type 1 (HIV-1) Infected Participants Receiving Care in a Test and Treat Model of Care","status":"COMPLETED","sponsor":"Janssen Scientific Affairs, LLC","startDate":"2017-07-31","conditions":"HIV-1","enrollment":109},{"nctId":"NCT02578550","phase":"PHASE1","title":"A Bioequivalence Study of Darunavir, Emtricitabine, and Tenofovir Alafenamide, in the Presence of Cobicistat in Healthy Participants","status":"COMPLETED","sponsor":"Janssen Sciences Ireland UC","startDate":"2015-11","conditions":"Healthy","enrollment":126},{"nctId":"NCT04661397","phase":"PHASE1","title":"A Study in Healthy Participants to Assess the Effect of Darunavir, Emtricitabine, and Tenofovir Alafenamide in the Presence of Cobicistat as Fixed Dose Combination (Darunavir/Cobicistat/Emtricitabine/Tenofovir Alafenamide) Compared With Co-administration of the Separate Agents","status":"COMPLETED","sponsor":"Janssen Research & Development, LLC","startDate":"2021-01-05","conditions":"Healthy","enrollment":37},{"nctId":"NCT02984852","phase":"PHASE1","title":"Study to Evaluate the Relative Bioavailability of Fixed-dose Combination Tablet Darunavir/Cobicistat/Emtricitabine/Tenofovir Alafenamide (D/C/F/TAF) as a Whole Tablet, as a Split Tablet, and as Crushed Tablet in Healthy Adult Participants","status":"COMPLETED","sponsor":"Janssen Scientific Affairs, LLC","startDate":"2016-12","conditions":"Healthy","enrollment":30},{"nctId":"NCT02403674","phase":"PHASE3","title":"Comparison of Doravirine, Tenofovir, Lamivudine (MK-1439A) and ATRIPLA™ in Treatment-Naive Human Immunodeficiency Virus Type 1 (HIV-1)-Infected Participants (MK-1439A-021)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2015-06-05","conditions":"Human Immunodeficiency Virus (HIV)","enrollment":734},{"nctId":"NCT04585737","phase":"PHASE4","title":"Efficacy of Switching to DTG/3TC in Virologically-suppressed Adults Currently on B/F/TAF","status":"COMPLETED","sponsor":"Charlotte-Paige Rolle, MD","startDate":"2020-10-05","conditions":"HIV I Infection","enrollment":222},{"nctId":"NCT01380080","phase":"PHASE4","title":"REMEMBER: Reducing Early Mortality & Morbidity by Empiric Tuberculosis (TB) Treatment","status":"COMPLETED","sponsor":"Advancing Clinical Therapeutics Globally for HIV/AIDS and Other Infections","startDate":"2011-10","conditions":"HIV Infection","enrollment":851},{"nctId":"NCT03577470","phase":"","title":"An Italian Observation of Antiretroviral Treatment in Participants Taking Darunavir/ Cobicistat Plus Emtricitabine and Tenofovir Alafenamide Fumarate","status":"COMPLETED","sponsor":"Janssen-Cilag S.p.A.","startDate":"2018-06-13","conditions":"Human Immunodeficiency Virus (HIV)","enrollment":246},{"nctId":"NCT04143594","phase":"PHASE2","title":"Study to Evaluate the Safety and Efficacy of Lenacapavir (GS-6207) in Combination With Other Antiretroviral Agents in People Living With HIV","status":"COMPLETED","sponsor":"Gilead Sciences","startDate":"2019-11-22","conditions":"HIV-1-infection","enrollment":183},{"nctId":"NCT03960645","phase":"PHASE1","title":"Study to Evaluate the Pharmacokinetics (PK), Safety, and Efficacy of B/F/TAF in Human Immunodeficiency Virus (HIV)-1 Infected, Virologically Suppressed, Pregnant Women in Their Second and Third Trimesters","status":"COMPLETED","sponsor":"Gilead Sciences","startDate":"2019-06-28","conditions":"HIV-1-infection","enrollment":62},{"nctId":"NCT04388904","phase":"PHASE4","title":"Rapid Reinitiation of a Single Tablet Antiretroviral Therapy Using Symtuza® in HIV-1 Infected Treatment-Experienced Patients Off Therapy. (ReSTART)","status":"COMPLETED","sponsor":"The Crofoot Research Center, Inc.","startDate":"2021-09-01","conditions":"HIV-1-infection","enrollment":75},{"nctId":"NCT01910402","phase":"PHASE3","title":"A Study to Determine Safety and Efficacy of Dolutegravir/Abacavir/Lamivudine (DTG/ABC/3TC) in Human Immunodeficiency Virus (HIV)-1 Infected Antiretroviral Therapy (ART) Naïve Women (ARIA)","status":"COMPLETED","sponsor":"ViiV Healthcare","startDate":"2013-08-22","conditions":"Infection, Human Immunodeficiency Virus, HIV Infections","enrollment":499},{"nctId":"NCT02831764","phase":"PHASE3","title":"An Efficacy, Safety, and Tolerability Study Comparing Dolutegravir (DTG) Plus Lamivudine (3TC) With Dolutegravir Plus Tenofovir/Emtricitabine in Treatment naïve HIV Infected Participants (Gemini 2)","status":"COMPLETED","sponsor":"ViiV Healthcare","startDate":"2016-07-18","conditions":"Infection, Human Immunodeficiency Virus, HIV Infections","enrollment":722},{"nctId":"NCT02831673","phase":"PHASE3","title":"An Efficacy, Safety, and Tolerability Study Comparing Dolutegravir Plus Lamivudine With Dolutegravir Plus Tenofovir/Emtricitabine in Treatment naïve HIV Infected Subjects (Gemini 1)","status":"COMPLETED","sponsor":"ViiV Healthcare","startDate":"2016-07-21","conditions":"Infection, Human Immunodeficiency Virus, HIV Infections","enrollment":719},{"nctId":"NCT03656783","phase":"PHASE3","title":"Effects of Biktarvy on CFR in Stable HIV Patients","status":"COMPLETED","sponsor":"Brigham and Women's Hospital","startDate":"2018-09-14","conditions":"HIV","enrollment":25},{"nctId":"NCT04040075","phase":"PHASE4","title":"Testing the Safety and Efficacy of Commercial Drug Biktarvy in Subjects Known to Have the 184 Resistance Mutation to a Component in Biktarvy","status":"TERMINATED","sponsor":"Southampton Healthcare, Inc.","startDate":"2019-07-01","conditions":"HIV-1-infection","enrollment":12},{"nctId":"NCT03227731","phase":"PHASE2, PHASE3","title":"Immediate or Deferred Pre-exposure Prophylaxis for HIV Prevention: Safe Options for Pregnant and Lactating Women","status":"COMPLETED","sponsor":"University of KwaZulu","startDate":"2017-09-28","conditions":"HIV-1-infection","enrollment":540},{"nctId":"NCT02431247","phase":"PHASE3","title":"A Study to Evaluate Efficacy and Safety of Darunavir/Cobicistat/Emtricitabine/Tenofovir Alafenamide (D/C/F/TAF) Fixed Dose Combination (FDC) Versus a Regimen Consisting of Darunavir/Cobicistat FDC With Emtricitabine/Tenofovir Disoproxil Fumarate FDC in Treatment-naive HIV Type 1 Infected Subjects","status":"COMPLETED","sponsor":"Janssen Sciences Ireland UC","startDate":"2015-07-06","conditions":"Immunodeficiency Virus Type 1, Human","enrollment":725},{"nctId":"NCT04222283","phase":"PHASE4","title":"Switch to TAF+FTC+BIC in HIV-1-infected Patients Over 65 Years Old at Risk of Polymedication","status":"UNKNOWN","sponsor":"Institut de Médecine et d'Epidémiologie Appliquée - Fondation Internationale Léon M'Ba","startDate":"2020-08-17","conditions":"HIV Infections","enrollment":27},{"nctId":"NCT02607956","phase":"PHASE3","title":"Study to Evaluate the Safety and Efficacy of Bictegravir/Emtricitabine/Tenofovir Alafenamide Versus Dolutegravir + Emtricitabine/Tenofovir Alafenamide in Human Immunodeficiency Virus (HIV-1) Infected, Antiretroviral Treatment-Naive Adults","status":"COMPLETED","sponsor":"Gilead Sciences","startDate":"2015-11-11","conditions":"HIV-1 Infection","enrollment":657},{"nctId":"NCT03110380","phase":"PHASE3","title":"Switching to a Fixed Dose Combination of Bictegravir/Emtricitabine/Tenofovir Alafenamide (B/F/TAF) in Human Immunodeficiency Virus Type 1 (HIV-1) Infected Adults Who Are Virologically Suppressed","status":"COMPLETED","sponsor":"Gilead Sciences","startDate":"2017-06-12","conditions":"HIV-1-infection","enrollment":567},{"nctId":"NCT02269917","phase":"PHASE3","title":"Study to Evaluate Efficacy and Safety of Darunavir/Cobicistat/Emtricitabine/Tenofovir Alafenamide (D/C/F/TAF) Regimen Versus Boosted Protease Inhibitor (bPI) Along With Emtricitabine/Tenofovir Disoproxil Fumarate (FTC/TDF) Regimen in Virologically-Suppressed, HIV-1 Infected Participants","status":"COMPLETED","sponsor":"Janssen R&D Ireland","startDate":"2015-03","conditions":"Human Immunodeficiency Virus Type 1","enrollment":1149},{"nctId":"NCT03631732","phase":"PHASE3","title":"Study to Evaluate Switching From a Regimen of Two Nucleos(t)Ide Reverse Transcriptase Inhibitors (NRTI) Plus a Third Agent to a Fixed Dose Combination (FDC) of Bictegravir/Emtricitabine/Tenofovir Alafenamide (B/F/TAF), in Virologically-Suppressed, HIV-1 Infected African American Participants","status":"COMPLETED","sponsor":"Gilead Sciences","startDate":"2018-08-28","conditions":"HIV-1 Infection","enrollment":496},{"nctId":"NCT04006704","phase":"PHASE1","title":"Study to Assess the Acceptability of Darunavir/Cobicistat/Emtricitabine/Tenofovir Alafenamide (D/C/F/TAF) Fixed-Dose Combination (FDC) Tablets in Human Immunodeficiency Virus Type 1 (HIV-1) Infected Pediatric Participants, Using Matching Placebo Tablets","status":"COMPLETED","sponsor":"Janssen Pharmaceutica N.V., Belgium","startDate":"2019-10-10","conditions":"HIV-1","enrollment":25},{"nctId":"NCT01815736","phase":"PHASE3","title":"Study to Evaluate Switching From a TDF-Containing Combination Regimen to a TAF-Containing Fixed Dose Combination (FDC) in Virologically-Suppressed, HIV-1 Positive Participants","status":"COMPLETED","sponsor":"Gilead Sciences","startDate":"2013-03-27","conditions":"HIV, HIV Infections","enrollment":1443},{"nctId":"NCT02104700","phase":"PHASE2, PHASE3","title":"Switch From Nevirapine-based Regimen to Once a Day Rilpivirine/Emtricitabine/Tenofovir","status":"COMPLETED","sponsor":"Philip Grant","startDate":"2014-04","conditions":"HIV","enrollment":150},{"nctId":"NCT01709084","phase":"PHASE3","title":"A Clinical Trial Comparing the Efficacy of Tenofovir Disoproxil Fumarate/Emtricitabine/Rilpivirine (TDF/FTC/RPV) Versus TDF/FTC/Efavirenz (TDF/FTC/EFV) in Patients With Undetectable Plasma HIV-1 RNA on Current First-line Treatment","status":"COMPLETED","sponsor":"Janssen-Cilag International NV","startDate":"2013-10-02","conditions":"Human Immunodeficiency Virus-type 1 Infection","enrollment":426},{"nctId":"NCT02603107","phase":"PHASE3","title":"Study to Evaluate the Safety and Efficacy of Switching From Regimens Consisting of Boosted Atazanavir or Darunavir Plus Either Emtricitabine/Tenofovir or Abacavir/Lamivudine to Bictegravir/Emtricitabine/Tenofovir Alafenamide in Virologically Suppressed HIV-1 Infected Adults","status":"COMPLETED","sponsor":"Gilead Sciences","startDate":"2015-11-20","conditions":"HIV-1 Infection","enrollment":578},{"nctId":"NCT03405935","phase":"PHASE3","title":"Study to Evaluate Switching From an E/C/F/TAF Fixed-Dose Combination (FDC) Regimen or a TDF Containing Regimen to B/F/TAF FDC in Human Immunodeficiency Virus-1 (HIV-1) Infected Participants Aged ≥ 65 Years","status":"COMPLETED","sponsor":"Gilead Sciences","startDate":"2018-03-01","conditions":"HIV-1 Infection","enrollment":86},{"nctId":"NCT02603120","phase":"PHASE3","title":"Safety and Efficacy of Switching From Dolutegravir and ABC/3TC or ABC/DTG/3TC to B/F/TAF in HIV-1 Infected Adults Who Are Virologically Suppressed","status":"COMPLETED","sponsor":"Gilead Sciences","startDate":"2015-11-11","conditions":"HIV-1 Infection","enrollment":567},{"nctId":"NCT02600819","phase":"PHASE3","title":"Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Efficacy of E/C/F/TAF Fixed Dose Combination (FDC) in HIV-1 Infected Adults on Chronic Hemodialysis","status":"COMPLETED","sponsor":"Gilead Sciences","startDate":"2015-12-14","conditions":"HIV-1 Infection","enrollment":55},{"nctId":"NCT02616029","phase":"PHASE3","title":"Study to Evaluate Switching to Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Alafenamide (E/C/F/TAF) Fixed Dose Combination (FDC) in Virologically-Suppressed HIV-1 Infected Adults Harboring the Archived Isolated NRTI Resistance Mutation M184V/M184I","status":"COMPLETED","sponsor":"Gilead Sciences","startDate":"2015-12-17","conditions":"HIV-1 Infection","enrollment":66},{"nctId":"NCT04236453","phase":"PHASE1","title":"A Study in Healthy Participants to Assess the Effect of Darunavir, Emtricitabine, and Tenofovir Alafenamide in the Presence of Cobicistat When Administered as a Fixed Dose Combination (Darunavir/Cobicistat/Emtricitabine/Tenofovir Alafenamide) Compared to the Co-administration of the Separate Agents","status":"TERMINATED","sponsor":"Janssen Pharmaceutica N.V., Belgium","startDate":"2020-01-23","conditions":"Healthy","enrollment":16},{"nctId":"NCT02397694","phase":"PHASE2","title":"Safety and Efficacy of Bictegravir + Emtricitabine/Tenofovir Alafenamide Versus Dolutegravir + Emtricitabine/Tenofovir Alafenamide in HIV-1 Infected, Antiretroviral Treatment-Naive Adults","status":"COMPLETED","sponsor":"Gilead Sciences","startDate":"2015-03-23","conditions":"HIV-1 Infection","enrollment":98},{"nctId":"NCT02121795","phase":"PHASE3","title":"Switch Study to Evaluate F/TAF in HIV-1 Positive Participants Who Are Virologically Suppressed on Regimens Containing FTC/TDF","status":"COMPLETED","sponsor":"Gilead Sciences","startDate":"2014-05-06","conditions":"HIV-1 Infection","enrollment":668},{"nctId":"NCT02616783","phase":"PHASE3","title":"Switching From a Tenofovir Disoproxil Fumarate (TDF) Containing Regimen to Elvitegravir/Cobicistat/Emtricitabine/ Tenofovir Alafenamide (E/C/F/TAF) Fixed-Dose Combination (FDC) in Virologically-Suppressed, HIV-1 Infected Adults Aged ≥ 60 Years","status":"COMPLETED","sponsor":"Gilead Sciences","startDate":"2015-12-22","conditions":"HIV-1 Infection","enrollment":167},{"nctId":"NCT02652624","phase":"PHASE3","title":"Safety and Efficacy of Switching to a FDC of B/F/TAF From E/C/F/TAF, E/C/F/TDF, or ATV+RTV+FTC/TDF in Virologically Suppressed HIV-1 Infected Women","status":"COMPLETED","sponsor":"Gilead Sciences","startDate":"2016-02-19","conditions":"HIV-1 Infection","enrollment":472},{"nctId":"NCT01818596","phase":"PHASE3","title":"Open-label Safety Study of E/C/F/TAF (Genvoya®) in HIV-1 Positive Patients With Mild to Moderate Renal Impairment","status":"COMPLETED","sponsor":"Gilead Sciences","startDate":"2013-03-27","conditions":"HIV, HIV Infections","enrollment":252},{"nctId":"NCT01797445","phase":"PHASE3","title":"Study to Evaluate the Safety and Efficacy of E/C/F/TAF Versus E/C/F/TDF in HIV-1 Positive, Antiretroviral Treatment-Naive Adults","status":"COMPLETED","sponsor":"Gilead Sciences","startDate":"2013-03-12","conditions":"HIV, HIV Infections","enrollment":872},{"nctId":"NCT02345252","phase":"PHASE3","title":"Switch Study to Evaluate the Safety and Efficacy of Emtricitabine/Rilpivirine/Tenofovir Alafenamide (FTC/RPV/TAF) Fixed Dose Combination (FDC) in HIV-1 Positive Adults Who Are Virologically Suppressed on Emtricitabine/Rilpivirine/Tenofovir Disoproxil Fumarate (FTC/RPV/TDF)","status":"COMPLETED","sponsor":"Gilead Sciences","startDate":"2015-01-26","conditions":"HIV-1 Infection","enrollment":632},{"nctId":"NCT02345226","phase":"PHASE3","title":"Study to Evaluate Switching From a Regimen Consisting of Efavirenz/Emtricitabine/Tenofovir Disoproxil Fumarate (EFV/FTC/TDF) Fixed Dose Combination (FDC) to Emtricitabine/Rilpivirine/Tenofovir Alafenamide (FTC/RPV/TAF) FDC in Virologically-Suppressed, HIV-1 Infected Adults","status":"COMPLETED","sponsor":"Gilead Sciences","startDate":"2015-01-26","conditions":"HIV-1 Infection","enrollment":881},{"nctId":"NCT02469246","phase":"PHASE3","title":"Switch Study to Evaluate F/TAF in HIV-1 Infected Adults Who Are Virologically Suppressed on Regimens Containing ABC/3TC","status":"COMPLETED","sponsor":"Gilead Sciences","startDate":"2015-06-29","conditions":"HIV-1 Infection","enrollment":567},{"nctId":"NCT01705574","phase":"PHASE3","title":"Safety and Efficacy of E/C/F/TDF Versus RTV-Boosted ATV Plus FTC/TDF in HIV-1 Infected, Antiretroviral Treatment-Naive Women","status":"COMPLETED","sponsor":"Gilead Sciences","startDate":"2012-10-24","conditions":"Acquired Immunodeficiency Syndrome, HIV Infections","enrollment":583},{"nctId":"NCT02993237","phase":"PHASE1","title":"Study to Assess the Acceptability/Swallowability of DRV-Containing FDC Tablets in HIV-1 Infected Adolescents, Using Matching Placebo Tablets","status":"COMPLETED","sponsor":"Janssen Research & Development, LLC","startDate":"2017-01-23","conditions":"HIV-1","enrollment":27},{"nctId":"NCT01497899","phase":"PHASE2","title":"Safety and Efficacy of E/C/F/TAF (Genvoya®) Versus E/C/F/TDF (Stribild®) in HIV-1 Infected, Antiretroviral Treatment-Naive Adults","status":"COMPLETED","sponsor":"Gilead Sciences","startDate":"2011-12-28","conditions":"Acquired Immunodeficiency Syndrome, HIV Infections","enrollment":279},{"nctId":"NCT02276612","phase":"PHASE2, PHASE3","title":"Efficacy and Safety of Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Alafenamide in HIV-1 Infected Adolescents","status":"COMPLETED","sponsor":"Gilead Sciences","startDate":"2014-12-03","conditions":"HIV","enrollment":60},{"nctId":"NCT01780506","phase":"PHASE3","title":"Study to Evaluate the Safety and Efficacy of E/C/F/TAF (Genvoya®) Versus E/C/F/TDF (Stribild®) in HIV-1 Positive, Antiretroviral Treatment-Naive Adults","status":"COMPLETED","sponsor":"Gilead Sciences","startDate":"2012-12-26","conditions":"HIV, HIV Infections","enrollment":872},{"nctId":"NCT02071082","phase":"PHASE3","title":"Efficacy and Safety of E/C/F/TAF (Genvoya®) in HIV-1/Hepatitis B Co-infected Adults","status":"COMPLETED","sponsor":"Gilead Sciences","startDate":"2014-02-25","conditions":"HIV, HBV","enrollment":79},{"nctId":"NCT01968551","phase":"PHASE3","title":"Phase 3 Open-Label Study to Evaluate Switching From Optimized Stable Antiretroviral Regimens Containing Darunavir to Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Alafenamide (E/C/F/TAF) Fixed Dose Combination (FDC) Plus Darunavir (DRV) in Treatment Experienced HIV-1 Positive Adults","status":"COMPLETED","sponsor":"Gilead Sciences","startDate":"2013-09-03","conditions":"HIV-1, HIV Infections, Acquired Immunodeficiency Syndrome","enrollment":158},{"nctId":"NCT02707601","phase":"PHASE3","title":"Efficacy, Safety, and Tolerability of Ledipasvir/Sofosbuvir (LDV/SOF) Treatment for HIV/HCV Co-infected Participants Who Switch to Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Alafenamide (E/C/F/TAF) or Emtricitabine/Rilpivirine/Tenofovir Alafenamide (F/R/TAF) Prior to LDV/SOF HCV Treatment","status":"COMPLETED","sponsor":"Gilead Sciences","startDate":"2016-04-01","conditions":"HIV-1 Infection, HCV Infection","enrollment":150},{"nctId":"NCT02605954","phase":"PHASE3","title":"Safety and Efficacy of Switching From Regimens of ABC/3TC + a 3rd Agent to E/C/F/TAF Fixed-Dose Combination (FDC) in Virologically-Suppressed HIV 1 Infected Adults","status":"COMPLETED","sponsor":"Gilead Sciences","startDate":"2015-11-18","conditions":"HIV-1 Infection","enrollment":275},{"nctId":"NCT01403051","phase":"PHASE2","title":"High Dose Vitamin D and Calcium for Bone Health in Individuals Initiating HAART","status":"COMPLETED","sponsor":"Advancing Clinical Therapeutics Globally for HIV/AIDS and Other Infections","startDate":"2011-09","conditions":"HIV-1 Infection","enrollment":167},{"nctId":"NCT02770508","phase":"PHASE4","title":"Darunavir/Ritonavir + Lamivudine Versus Darunavir/Ritonavir +Emtricitabine/Tenofovir in Naïve HIV-1 Infected Subjects","status":"COMPLETED","sponsor":"Fundación Huésped","startDate":"2015-11","conditions":"HIV-1 Infection","enrollment":145},{"nctId":"NCT01450189","phase":"NA","title":"A Key Link for Transmission Prevention","status":"COMPLETED","sponsor":"University of North Carolina, Chapel Hill","startDate":"2011-10","conditions":"HIV","enrollment":46},{"nctId":"NCT02246998","phase":"PHASE4","title":"Renal Effect of Stribild or Other Tenofovir DF-containing Regimens Compared to Ritonavir-boosted Atazanavir Plus Abacavir/Lamivudine in Antiretroviral Treatment-naive HIV-1 Infected Adults","status":"COMPLETED","sponsor":"Gilead Sciences","startDate":"2014-12-15","conditions":"HIV-1 Infection","enrollment":72},{"nctId":"NCT01231555","phase":"PHASE2","title":"Dose-finding Study of GSK2248761 in Antiretroviral Therapy-Naive Subjects (SIGNET)","status":"TERMINATED","sponsor":"ViiV Healthcare","startDate":"2010-11-18","conditions":"Infection, Human Immunodeficiency Virus","enrollment":23},{"nctId":"NCT02475135","phase":"PHASE1","title":"Relative Bioavailability and Food Effect for Darunavir/Cobicistat/Emtricitabine/Tenofovir Alafenamide Fixed Dose Combination","status":"COMPLETED","sponsor":"Janssen Sciences Ireland UC","startDate":"2015-06-01","conditions":"Healthy","enrollment":72},{"nctId":"NCT00924898","phase":"PHASE4","title":"Treatment of Acute HIV With Emtricitabine, Tenofovir and Efavirenz (CID 0805)","status":"COMPLETED","sponsor":"University of North Carolina, Chapel Hill","startDate":"2005-01","conditions":"Acute HIV Infection, HIV Infections","enrollment":92},{"nctId":"NCT01694420","phase":"PHASE3","title":"Treatment of Acute HIV Infection With Quad Fixed-dose Combination (FDC) Tablet","status":"COMPLETED","sponsor":"Duke University","startDate":"2012-09","conditions":"HIV","enrollment":33},{"nctId":"NCT00116805","phase":"PHASE3","title":"A Study to Compare Tenofovir Disoproxil Fumarate Versus Adefovir Dipivoxil for the Treatment of HBeAg-Positive Chronic Hepatitis B","status":"COMPLETED","sponsor":"Gilead Sciences","startDate":"2005-06","conditions":"Chronic Hepatitis B","enrollment":266},{"nctId":"NCT00117676","phase":"PHASE3","title":"A Study to Compare Tenofovir Disoproxil Fumarate Versus Adefovir Dipivoxil for the Treatment of HBeAg-Negative Chronic Hepatitis B","status":"COMPLETED","sponsor":"Gilead Sciences","startDate":"2005-02","conditions":"Chronic Hepatitis B","enrollment":382},{"nctId":"NCT02530060","phase":"PHASE4","title":"A Study to Evaluate the Pharmacokinetics of Rilpivirine/Tenofovir/Emtricitabine After a Single-Oral Administration in Healthy Japanese Adult Male Participants","status":"COMPLETED","sponsor":"Janssen Pharmaceutical K.K.","startDate":"2015-08","conditions":"Healthy","enrollment":8},{"nctId":"NCT01565850","phase":"PHASE2","title":"D/C/F/TAF Versus COBI-boosted DRV Plus FTC/TDF in HIV-1 Infected, Antiretroviral Treatment Naive Adults","status":"COMPLETED","sponsor":"Gilead Sciences","startDate":"2012-04","conditions":"Acquired Immunodeficiency Syndrome, HIV Infections","enrollment":153},{"nctId":"NCT01565889","phase":"PHASE1, PHASE2","title":"Part A: Drug Interaction Study of Sofosbuvir and Antiretroviral Therapy (ART) Combinations in HIV and Hepatitis C Virus (HCV) Co-infected Patients. Part B: Efficacy and Safety of Sofosbuvir for 12 Weeks in HIV/HCV Co-infected Patients.","status":"COMPLETED","sponsor":"Gilead Sciences","startDate":"2012-03","conditions":"Hepatitis C, HIV","enrollment":52},{"nctId":"NCT00298363","phase":"PHASE2","title":"Study Comparing Tenofovir Disoproxil Fumarate (TDF), Emtricitabine (FTC)/TDF, and Entecavir (ETV) in the Treatment of Chronic HBV in Subjects With Decompensated Liver Disease.","status":"COMPLETED","sponsor":"Gilead Sciences","startDate":"2006-04","conditions":"Chronic Hepatitis B","enrollment":112},{"nctId":"NCT00323687","phase":"PHASE4","title":"SONETT: Switch Study to Once Daily HIV Treatment Regimen With Truvada","status":"COMPLETED","sponsor":"Gilead Sciences","startDate":"2004-09","conditions":"HIV-1 Infection","enrollment":50}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":1,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_3","status":"active","brandName":"FTC/TDF FDC","genericName":"FTC/TDF FDC","companyName":"Janssen Sciences Ireland UC","companyId":"janssen-sciences-ireland-uc","modality":"Small molecule","firstApprovalDate":"","aiSummary":"FTC/TDF is a fixed-dose combination of two nucleoside reverse transcriptase inhibitors that block HIV reverse transcriptase to prevent viral replication. Used for HIV-1 infection (treatment), HIV-1 pre-exposure prophylaxis (PrEP).","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}